Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
34 results
D3.34 - Cephalosporine drug provocation in a population of children with confirmed serum sickness-like reaction to amoxicillin
D3.35 - Severe atopic dermatitis poorly controlled, or something else?
D3.36 - Contact allergy to sodium metabisulfite in Singapore: A single-center retrospective study of patch test data from 2004 to 2021
D3.37 - Beware of the Rare: AGEP
D3.39 - Autoimmune Progesterone Dermatitis Case Report
D3.42 - Symmetrical drug-related intertriginous and flexural exanthema related to symptomatic slow-acting drug for osteoarthritis (SYSADOA) – a case report
D3.44 - The Role of Medical History and Diagnostic Testing in Identifying Post-Surgical Allergic Reactions
D3.45 - Perioperative Immediate Hypersensitivity Reactions: First Chilean Cohort Study 2020-2024 Clinical Hospital University of Chile
- D3.100 - Risk Factors and Biomarkers for COVID-19 and Allergic Diseases
- D3.102 - PROMs Improvement Effects of Biologics in Chronic Rhinosinusitis with Nasal Polyps Patients: Real-life Experience
- D3.103 - Impact of aspirin-induced bronchospasm on the in vitro Aspirin Hypersensitivity Diagnostic Index in the patients with Aspirin Exacerbated Respiratory Disease
- D3.104 - A step towards standardized Clinical Remission Criteria for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): insights from a real-life study
- D3.105 - Suspected EGPA in a patient on Dupilumab treatment: confirmed diagnosis of sarcoidosis - case report
- D3.106 - Real-World Dupilumab Effectiveness Through 18 Months in Patients with CRSwNP and Coexisting Asthma: Results from the Global AROMA Registry
- D3.108 - PTGDR2 Blood Expression as a Potential Biomarker for Predicting Super-Response to IL-5-Targeted Therapies in Severe Asthma
D3.109 - Lichen planus following dupilumab treatment in patients with severe asthma and nasal sinus polyposis
- D3.110 - Contribution of biotherapies in the reintroduction of NSAIDs in patients with moderate to severe asthma, hypersensitive to COX-1 inhibitor NSAIDs
- D3.111 - Lymphocyte profile and asthma control during the treatment with benralizumab in real life
- D3.112 - Role of nasal cytology in patients with bronchial asthma
- D3.113 - In silico system pharmacology modeling provides insights into a mechanism for greater potency of TSLP/TSLPR pathway inhibition with verekitug, a novel antibody antagonist of TSLPR, as compared to tezepelumab
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download